Effects of treatment with acamprosate on β-endorphin plasma concentration in humans with high alcohol preference

Neuroscience Letters

Volumn 404, Issue 1-2, 2006, Pages 103-106

  Kiefer, Falk ^a,b   Jahn, Holger ^b   Otte, Christian ^b   Nakovics, Helmut ^a   Wiedemann, Klaus ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF HAMBURG   (Germany)

Author keywords

Endorphin; Acamprosate; Alcohol

Indexed keywords

ACAMPROSATE; ALCOHOL; BETA ENDORPHIN; OPIATE RECEPTOR; PLACEBO;

ADULT; ALCOHOL CONSUMPTION; ALCOHOL WITHDRAWAL; ALCOHOLISM; ANXIETY DISORDER; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROMODULATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEFICIENCY; SAMPLE; WITHDRAWAL SYNDROME;

ADULT; ALCOHOL DETERRENTS; ALCOHOL DRINKING; ALCOHOLISM; ANIMALS; BETA-ENDORPHIN; BIOLOGICAL MARKERS; FEMALE; HUMANS; MALE; MIDDLE AGED; PLACEBOS; RATS; TAURINE;

EID: 33745902842     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2006.05.015     Document Type: Article

References (25)

1. Adinoff B., Iranmanesh A., Veldhuis J., and Fisher L. Disturbance of the stress response. The role of the HPA axis during alcohol withdrawal and abstinence. Alcohol Health Res. World 22 1 (1998) 67-72
2. Adinoff B., Junghanns K., Kiefer F., and Krishnan-Sarin S. Suppression of the HPA axis stress-response: implications for relapse. Alcohol Clin. Exp. Res. 29 7 (2005) 1351-1355
3. Costa G., Saija A., Padovano I., Trimarchi G.R., De Pasquale R., and Caputi A.P. The calcium antagonist nimodipine increases beta-endorphin release from rat hypophysis through an action on adrenal glands. An "in vivo" and "in vitro" study. Pharmacol. Res. Commun. 16 (1984) 959-968
4. Dai X., Thavundayil J., and Gianoulakis C. Differences in the peripheral levels of beta-endorphin in response to alcohol and stress as a function of alcohol dependence and family history of alcoholism. Alcohol Clin. Exp. Res. 29 11 (2005) 1965-1975
5. De Witte P., Bachteler D., and Spanagel R. Acamprosate: preclinical data. In: Spanagel R., and Mann K. (Eds). Drugs for Relapse Prevention of Alcoholism (2005), Birkhauser Basel, Boston, Berlin
6. Gewiss M., Heidbreder C., Opsomer L., Durbin P., and De Witte P. Acamprosate and diazepam differentially modulate alcohol-induced behavioural and cortical alterations in rats following chronic inhalation of ethanol vapour. Alcohol Alcohol. 26 (1991) 129-137
7. Gianoulakis C., Krishnan B., and Thavundayil J. Enhanced sensitivity of pituitary beta-endorphin to ethanol in subjects at high risk of alcoholism. Arch. Gen. Psychiatry 53 3 (1996) 250-257
8. Heinz A., Reimold M., Wrase J., Hermann D., Croissant B., Mundle G., Dohmen B.M., Braus D.F., Schumann G., Machulla H.J., Bares R., and Mann K. Correlation of stable elevations in striatal mu-opioid receptor availability in detoxified alcoholic patients with alcohol craving: a positron emission tomography study using carbon 11-labeled carfentanil. Arch. Gen. Psychiatry 62 1 (2005) 57-64
9. Kiefer F., Horntrich M., Jahn H., and Wiedemann K. Is withdrawal-induced anxiety in alcoholism based on β-endorphin deficiency?. Psychopharmacology 162 (2002) 433-437
10. Kiefer F., Jahn H., Holzbach R., Briken P., Stracke R., and Wiedemann K. Die NACALM-Studie: Wirksamkeit, Vertraglichkeit, outcome. Sucht 49 (2003) 342-351
11. Kiefer F., Jahn H., Tarnaske T., Helwig H., Briken P., Holzbach R., Kampf P., Stracke R., Baehr M., Naber D., and Wiedemann K. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch. Gen. Psychiatry 60 (2003) 92-99
12. Kiefer F., and Mann K. New achievements and pharmacotherapeutic approaches in the treatment of alcohol dependence. Eur. J. Pharmacol. 526 1-3 (2005) 163-171
13. Kiefer F., and Wiedemann K. Neuroendocrine pathways of addictive behaviour. Addict. Biol. 9 3-4 (2004) 205-212
14. Kratzer U., and Schmidt W.J. The anti-craving drug acamprosate inhibits the conditioned place aversion induced by naloxone-precipitated morphine withdrawal in rats. Neurosci. Lett. 252 (1998) 53-56
15. Littleton J. Acamprosate in alcohol dependence: how does it work?. Addiction 90 (1995) 1179-1188
16. Mann K., Lehert P., and Morgan M.Y. The efficacy of acamprosate in maintaining abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcohol. Clin. Exp. Res. 28 (2004) 51-63
17. Modesto-Lowe V., and Fritz E.M. The opioidergic-alcohol link: implications for treatment. CNS Drugs 19 8 (2005) 693-707
18. O'Malley S.S., Krishnan-Sarin S., Farren C., Sinha R., and Kreek J. Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis. Psychopharmacology 160 (2002) 19-29
19. Rammes G., Mahal B., Putzke J., Parsons C., Spielmanns P., Pestel E., Spanagel R., Zieglgansberger W., and Schadrack J. The anti-craving compound acamprosate acts as a weak NMDA-receptor antagonist, but modulates NMDA-receptor subunit expression similar to memantine and MK-801. Neuropharmacology 40 (2001) 749-760
20. Sanchis-Segura C., Grisel J.E., Olive M.F., Ghozland S., Koob G.F., Roberts A.J., and Cowen M.S. Role of the endogenous opioid system on the neuropsychopharmacological effects of ethanol: new insights about an old question. Alcohol Clin. Exp. Res. 29 8 (2005) 1522-1527
21. Schuckit M.A. Reactions to alcohol in sons of alcoholics and controls. Alcohol Clin. Exp. Res. 12 4 (1988) 465-470
22. Tomaszewska-Zaremba D., Przekop F., and Mateusiak K. The involvement of GABA (A) receptors in the control of GnRH and betaendorphin release, and catecholaminergic activity in ventromedialinfundibular region of hypothalamus in anestrous ewes. J. Physiol. Pharmacol. 52 (2001) 489-500
23. Verheul R., van den Brink W., and Geerlings P. A three-pathway psychobiological model of craving for alcohol. Alcohol Alcohol. 34 2 (1999) 197-222
24. Zalewska-Kaszubska J., Cwiek W., Dyr W., and Czarnecka E. Changes in the beta-endorphin plasma level after repeated treatment with acamprosate in rats selectively bred for high and low alcohol preference. Neurosci. Lett. 388 1 (2005) 45-48
25. Zeise M.L., Kasparov S., Capogna M., and Zieglgansberger W. Acamprosate (calcium acetylhomotaurinate) decreases postsynaptic potentials in the rat neocortex: possible involvement of excitatory amino acid receptors. Eur. J. Pharmacol. 231 (1993) 47-52